AI Article Synopsis
- The study aimed to assess how well the Bladder EpiCheck test performs in monitoring patients with non-muscle-invasive bladder cancer compared to traditional methods like urinary cytology and cystoscopy.
- Findings showed that the Bladder EpiCheck test had a higher sensitivity (62.3%) than cytology (33.3%) for detecting bladder cancer, especially in high-grade tumors, while cytology maintained higher specificity (98.6%).
- Overall, the combination of both tests improved sensitivity for detecting tumors, but the positive predictive value was better for cytology, while the negative predictive values were relatively similar for both tests.
Article Abstract
Background: The objective of this study was to evaluate the diagnostic accuracy of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer (NMIBC) and to compare it with the accuracy of urinary cytology, cystoscopy, and/or histology.
Methods: In total, 243 patients were enrolled in the current study. Patients were evaluated by voided urine cytology, by the Bladder EpiCheck test, and by white-light cystoscopy.
Results: Overall sensitivity was 33.3% for cytology, 62.3% for Bladder EpiCheck, and 66.7% for the 2 tests combined. The sensitivity of cytology increased from 7.7% in low-grade (LG) tumors to 66.6% in high-grade (HG) tumors; whereas, for the Bladder EpiCheck test, the sensitivity was 46.1% in LG tumors and 83.3% in HG tumors. Combined cytology and Bladder EpiCheck testing yielded an overall sensitivity of 56.4% for LG tumors and 90% for HG tumors. Overall specificity was 98.6% for cytology, 86.3% for Bladder EpiCheck, and 85.6% for the 2 tests combined. The positive predictive value was 92% for cytology and 68.2% for Bladder EpiCheck. For the 2 tests combined, it was 68.6%. The negative predictive value was similar for the 2 tests: 75.8% for cytology, 82.9% for Bladder EpiCheck, and 84.5% for the 2 tests combined.
Conclusions: The sensitivity of the Bladder EpiCheck test was significantly higher than that of cytology. The test performed very well in terms of specificity but could not reach the high value of cytology. The positive predictive value was higher for Bladder EpiCheck, whereas the negative predictive value was approximately the same for both tests.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncy.22152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Simultaneous Use of Bladder Epicheck and Urinary Cytology Can Improve the Sensitivity and Specificity of Diagnostic Follow-Up of Urothelial Lesions: Up-to-Date Data from a Multi-Institutional Cohort.
Diseases
September 2024
Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Bladder cancer is a prevalent urinary system malignancy and urinary cytology is widely used for its screening and follow-up. A novel diagnostic tool called Bladder Epicheck (BE) is increasingly being used for monitoring the recurrence of non-muscle-invasive bladder cancer (NMIBC). The simultaneous use of BE and urinary cytology can increase the diagnostic performances in the follow-up of bladder neoplasms.
View Article and Find Full Text PDFClinical performance of Bladder EpiCheck™ versus voided urine cytology for detecting recurrence of nonmuscle invasive bladder cancer: Systematic review and meta-analysis.
Urol Oncol
December 2024
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background: Nonmuscle invasive bladder cancer (NMIBC) has a favorable prognosis but has high propensity for recurrence. Recent development in one of the urinary biomarker tests, Bladder EpiCheck™, offers a noninvasive and accurate method to detect NMIBC recurrence. In this study, we aimed to compare the diagnostic performance of Bladder EpiCheck™ with urine cytology to detect NMIBC recurrence.
View Article and Find Full Text PDFTransforming UTUC diagnostics: the potential of bladder Epicheck® in clinical practice.
Minerva Urol Nephrol
October 2024
Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays.
Bladder Cancer
March 2024
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: An important reason for the high health care costs associated with bladder cancer is the need for frequent cystoscopy for detection and surveillance of this disease. Cytologic analysis of voided urine specimens can assist, but is too inaccurate to replace cystoscopy. In an effort to create reliable, objective, noninvasive mechanisms for detecting bladder cancer, a number of urine-based molecular tests have been developed with the ultimate goal of reducing the frequency of cystoscopy.
View Article and Find Full Text PDFUse of Bladder Epicheck® in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review.
Actas Urol Esp (Engl Ed)
October 2024
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Introduction: In recent years, different urinary markers such as the Bladder Epicheck® have been developed in an attempt to reduce the number of cystoscopies in the follow-up of non-muscle invasive bladder cancer (NMIBC).
Aim: To provide a systematic review of Bladder Epicheck® and its current clinical utility in the follow-up and detection of recurrence of NMIBC.
Material And Methods: Systematic review based on a literature search of PubMed, Web of Science and Scopus databases until October 2023, according to PRISMA and Quadas-2 criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!